Spotlight on Nephrology

Camille Nelson Kotton, MD, FIDSA, FAST
Credits: 0.75 CME / MOC / CNE / CPE
Redefining the Management of CMV in SOT: Emerging Options for High-Risk Patients: A Care Team Forum℠
Camille Nelson Kotton, MD, FIDSA, FAST
RMEI Medical Education, LLC

Redefining the Management of CMV in SOT: Emerging Options for High-Risk Patients: A Care Team Forum℠

Start

Activity Details

Free CME/MOC/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
0.75 ANCC Contact Hour(s)
0.75 ACPE Contact Hour(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
  • Identify risk factors and emerging therapies for resistant CMV disease

Activity Description

This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Hookipa, Merck, Shire/Takeda (Consultant).

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships with ineligible companies to disclose.

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Ansun, Merck, Novartis, Qiagen, Slieagen, Takeda, Whiscon (Grant/Research Support); Takeda (Advisor).

Patient
Patient participating in this activity has no relevant financial relationships with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-002-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For questions regarding this activity, please contact Linda Hopkins at lhopkins@rmei.com

Activity Details

Free CME/MOC/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
0.75 ANCC Contact Hour(s)
0.75 ACPE Contact Hour(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
  • Identify risk factors and emerging therapies for resistant CMV disease

Activity Description

This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Hookipa, Merck, Shire/Takeda (Consultant).

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships with ineligible companies to disclose.

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Ansun, Merck, Novartis, Qiagen, Slieagen, Takeda, Whiscon (Grant/Research Support); Takeda (Advisor).

Patient
Patient participating in this activity has no relevant financial relationships with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-002-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For questions regarding this activity, please contact Linda Hopkins at lhopkins@rmei.com

Nephrology Presentations

0.25 CME
Academy for Continued Healthcare Learning
Pathways to Improved Care in FSGS and IgAN – Latest Data in FSGS and IgAN

Pathways to Improved Care in FSGS and IgAN – Latest Data in FSGS and IgAN

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 13, 2022
Expires: April 13, 2023
15 minutes to complete

Accredited By

Target Audience

This activity is intended for nephrologists, and primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA Nephropathy.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
  • Outline emerging therapies and pathways for FSGS and IgAN
  • Interpret clinical trial data and endpoints from clinical trials with emerging therapies

Activity Description

Expert faculty, Dr. Richard Lafayette, explores clinical trial data coming out of a recent nephrology meeting, and provides learners with up-to-date knowledge on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). This brief interview-style video offers insights into the patient burden of chronic kidney disease, advances in understanding the pathophysiology, and emerging approaches to treatment for this patient population. Dr. Lafayette will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Statement of Educational Need

Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are no currently approved therapies and the management of FSGS and IgAN is challenging. Recent research has identified potential therapeutic targets for individuals with these progressive kidney diseases and there are a number of ongoing clinical trials. This education brings clinicians up-to-date on potential treatment targets and agents in the pipeline for progressive kidney disease.

Agenda

Dr. Lafayette will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Faculty

Richard Lafayette, MD
Stanford Department of Medicine, Nephrology
Stanford, CA

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:
Richard Lafayette, MD (Faculty)
Advisor or Review Panel member: Calliditas, Chinook, Novartis, Otsuka/Visterra, Travere, Vera
Consultant (Occasional): Novartis, Omeros
Grant/Research Support recipient: Calliditas, Chinook, Omeros, Otsuka/Visterra, Travere, Vera

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Travere Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 13, 2022
Expires: April 13, 2023
15 minutes to complete

Accredited By

Target Audience

This activity is intended for nephrologists, and primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA Nephropathy.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
  • Outline emerging therapies and pathways for FSGS and IgAN
  • Interpret clinical trial data and endpoints from clinical trials with emerging therapies

Activity Description

Expert faculty, Dr. Richard Lafayette, explores clinical trial data coming out of a recent nephrology meeting, and provides learners with up-to-date knowledge on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). This brief interview-style video offers insights into the patient burden of chronic kidney disease, advances in understanding the pathophysiology, and emerging approaches to treatment for this patient population. Dr. Lafayette will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Statement of Educational Need

Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are no currently approved therapies and the management of FSGS and IgAN is challenging. Recent research has identified potential therapeutic targets for individuals with these progressive kidney diseases and there are a number of ongoing clinical trials. This education brings clinicians up-to-date on potential treatment targets and agents in the pipeline for progressive kidney disease.

Agenda

Dr. Lafayette will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Faculty

Richard Lafayette, MD
Stanford Department of Medicine, Nephrology
Stanford, CA

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:
Richard Lafayette, MD (Faculty)
Advisor or Review Panel member: Calliditas, Chinook, Novartis, Otsuka/Visterra, Travere, Vera
Consultant (Occasional): Novartis, Omeros
Grant/Research Support recipient: Calliditas, Chinook, Omeros, Otsuka/Visterra, Travere, Vera

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Travere Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Jai Radhakrishnan, MD, MS, FASN
0.25 CME
Academy for Continued Healthcare Learning
Pathways to Improved Care in FSGS and IgAN – Highlights from Kidney Week

Pathways to Improved Care in FSGS and IgAN – Highlights from Kidney Week

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 9, 2021
Expires: November 9, 2022
15 minutes to complete

Accredited By

Target Audience

This activity is intended for nephrologists and primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA nephropathy.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
  • Outline emerging therapies and pathways for FSGS and IgAN
  • Interpret clinical trial data and endpoints from clinical trials with emerging therapies

Activity Description

Expert faculty, Dr. Jai Radhakrishnan, explores clinical trial data coming out of ASN 2021, and provides learners with up-to-date knowledge on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). This brief interview-style video offers insights into the patient burden of chronic kidney disease, advances in understanding the pathophysiology, and emerging approaches to treatment for this patient population. Dr. Radhakrishnan will discuss current barriers, emerging evidence, and strategies to incorporate advances.

This coverage is not sanctioned by the ASN Kidney Week conference organizers and is not an official part of the conference proceedings.

Statement of Educational Need

Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are no currently approved therapies and the management of FSGS and IgAN is challenging. Recent research has identified potential therapeutic targets for individuals with these progressive kidney diseases and there are a number of ongoing clinical trials. This education brings clinicians up-to-date on potential treatment targets and agents in the pipeline for progressive kidney disease.

Agenda

Dr. Radhakrishnan will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Faculty

Jai Radhakrishnan, MD, MS, FASN
Professor of Medicine
Columbia University Medical Center
Clinical Director, Nephrology Division
New York Presbyterian Hospital-Columbia
New York, NY

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:
Jai Radhakrishnan, MD, MS, FASN (Faculty)
Consultant (Occasional): Angion Biomedica, Aurinia Pharmaceuticals, GlaxoSmithKline, Equillium Bio, Reistone Biopharma, Sanofi Genzyme, Travere Therapeutics, Inc.
Grant/Research Support: Travere Therapeutics, Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Travere Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 9, 2021
Expires: November 9, 2022
15 minutes to complete

Accredited By

Target Audience

This activity is intended for nephrologists and primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA nephropathy.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
  • Outline emerging therapies and pathways for FSGS and IgAN
  • Interpret clinical trial data and endpoints from clinical trials with emerging therapies

Activity Description

Expert faculty, Dr. Jai Radhakrishnan, explores clinical trial data coming out of ASN 2021, and provides learners with up-to-date knowledge on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). This brief interview-style video offers insights into the patient burden of chronic kidney disease, advances in understanding the pathophysiology, and emerging approaches to treatment for this patient population. Dr. Radhakrishnan will discuss current barriers, emerging evidence, and strategies to incorporate advances.

This coverage is not sanctioned by the ASN Kidney Week conference organizers and is not an official part of the conference proceedings.

Statement of Educational Need

Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are no currently approved therapies and the management of FSGS and IgAN is challenging. Recent research has identified potential therapeutic targets for individuals with these progressive kidney diseases and there are a number of ongoing clinical trials. This education brings clinicians up-to-date on potential treatment targets and agents in the pipeline for progressive kidney disease.

Agenda

Dr. Radhakrishnan will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Faculty

Jai Radhakrishnan, MD, MS, FASN
Professor of Medicine
Columbia University Medical Center
Clinical Director, Nephrology Division
New York Presbyterian Hospital-Columbia
New York, NY

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:
Jai Radhakrishnan, MD, MS, FASN (Faculty)
Consultant (Occasional): Angion Biomedica, Aurinia Pharmaceuticals, GlaxoSmithKline, Equillium Bio, Reistone Biopharma, Sanofi Genzyme, Travere Therapeutics, Inc.
Grant/Research Support: Travere Therapeutics, Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Travere Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Camille Nelson Kotton, MD, FIDSA, FAST
0.75 CME / MOC / CNE / CPE
RMEI Medical Education, LLC
Redefining the Management of CMV in SOT: Emerging Options for High-Risk Patients: A Care Team Forum℠

Redefining the Management of CMV in SOT: Emerging Options for High-Risk Patients: A Care Team Forum℠

Start

Activity Details

Free CME/MOC/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
0.75 ANCC Contact Hour(s)
0.75 ACPE Contact Hour(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
  • Identify risk factors and emerging therapies for resistant CMV disease

Activity Description

This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Hookipa, Merck, Shire/Takeda (Consultant).

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships with ineligible companies to disclose.

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Ansun, Merck, Novartis, Qiagen, Slieagen, Takeda, Whiscon (Grant/Research Support); Takeda (Advisor).

Patient
Patient participating in this activity has no relevant financial relationships with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-002-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For questions regarding this activity, please contact Linda Hopkins at lhopkins@rmei.com

Activity Details

Free CME/MOC/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
0.75 ANCC Contact Hour(s)
0.75 ACPE Contact Hour(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
  • Identify risk factors and emerging therapies for resistant CMV disease

Activity Description

This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Hookipa, Merck, Shire/Takeda (Consultant).

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships with ineligible companies to disclose.

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Ansun, Merck, Novartis, Qiagen, Slieagen, Takeda, Whiscon (Grant/Research Support); Takeda (Advisor).

Patient
Patient participating in this activity has no relevant financial relationships with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-002-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For questions regarding this activity, please contact Linda Hopkins at lhopkins@rmei.com